Evidence map›Paper›PMID 41415832›Full record

ReviewFrontiers in nutrition2025

Targeting colorectal cancer with hesperidin and hesperetin: a comprehensive review of antiproliferative activity, chemopreventive, anti-inflammatory, and antioxidant effects.

Ming Qi, Yu Su

Abstract readReview
In one paragraph

Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ming QiDepartment of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Yu SuHangzhou Heyunjia Hospital, Hangzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) residues one of the leading reasons of cancer-related mortality worldwide, with increasing incidence attributed to dietary, environmental, and genetic factors. Despite advances in conventional therapies, including chemotherapy and targeted agents, treatment resistance and adverse side effects highlight the need for novel, safer, and more effective therapeutic strategies. Hesperidin (HSD) and hesperetin (HST), bioflavonoid abundantly found in citrus fruits, has emerged as a promising candidate due to its wide-ranging biological activities, particularly its role in modulating key molecular pathways involved in carcinogenesis. This comprehensive review explores the multifaceted anticancer potential of HSD and HST in the context of CRC, focusing on its ability to control programmed cell death mechanisms like autophagy and apoptosis, suppress chronic inflammation, and counteract oxidative stress-three pivotal hallmarks of tumor initiation and progression. Additionally, we examine the synergistic effects of HSD and HST with standard chemotherapeutic agents and its potential as a chemopreventive or adjuvant therapeutic compound. By consolidating preclinical and emerging clinical evidence, this review highlights the translational value of HSD and HST in CRC prevention and management. Understanding its molecular underpinnings may pave the way for HSD- and HST-based nutraceuticals and targeted therapies, contributing to a more personalized and integrative approach to CRC treatment.

Indexed as

anti-inflammatoryantioxidantapoptoticcolorectal cancerhesperidin

Identifiers

PMID41415832
PMCPMC12708268

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.